ArticleCancer biomarkers : section A of Disease markers2021
Clinical value of tumor-associated antigens and autoantibody panel combination detection in the early diagnostic of lung cancer.
Article in Cancer biomarkers : section A of Disease markers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Site-Specific Antigen Immobilization Improves Autoantibody Binding Efficiency on the Luminex Platform.ACS omega · 2026Article
- Machine Learning for Classification in Lung Cancer Using Routine Clinical and Laboratory Data.Annals of surgical oncology · 2026Article
- The value of an integrated multi-omics model in the diagnosis of benign and malignant pulmonary nodules.Translational cancer research · 2026Article
- Tumor antigen-associated autoantibodies: generation mechanisms, roles in tumorigenesis and progression, and clinical application prospects.Frontiers in immunology · 2026Review
- The B-cell-autoantibody axis in lung cancer immunity.Theranostics · 2026Review
- Multiple Tumor-related autoantibodies test enhances CT-based deep learning performance in diagnosing lung cancer with diameters < 70 mm: a prospective study in China.BMC pulmonary medicine · 2025Article
- Fusion of CT radiomics and autoantibody biomarkers for enhanced prediction of lung cancer diagnosis: a comprehensive study.Frontiers in oncology · 2025Article
- Clinical application of serum seven tumour-associated autoantibodies in patients with pulmonary nodules.Heliyon · 2024Article
- Efficacy of autoantibodies combined with tumor markers in the detection of lung cancer.Journal of clinical laboratory analysis · 2022Article
- Application Value Analysis of Seven-Autoantibody Panel in the Lung Cancer Screening in Yunnan.Computational intelligence and neuroscience · 2022Article
- Diagnostic value of conventional tumor markers in young patients with pulmonary nodules.Journal of clinical laboratory analysis · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study aimed to investigate the efficiency of combining tumor-associated antigens (TAAs) and autoantibodies in the diagnosis of lung cancer.
methodsThe serum levels of TAAs and seven autoantibodies (7-AABs) were detected from patients with lung cancer, benign lung disease and healthy controls. The performance of a new panel by combing TAAs and 7-AABs was evaluated for the early diagnosis of lung cancer.
resultsThe positive rate of 7-AABs was higher than the single detection of antibody. The positive rate of the combined detection of 7-AABs in lung cancer group (30.2%) was significantly higher than that of healthy controls (16.8%), but had no statistical difference compared with that of benign lung disease group (20.8%). The positive rate of 7-AABs showed a tendency to increase in lung cancer patients with higher tumor-node-metastasis (TNM) stages. For the pathological subtype analysis, the positive rate of 7-AABs was higher in patients with squamous cell carcinoma and small cell lung cancer than that of adenocarcinoma. The levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragment 211 (CYFRA 21-1) were significantly higher than that of benign lung disease and healthy control groups. An optimal model was established (including 7-AABs, CEA and CYFRA21-1) to distinguish lung cancer from control groups. The performance of this model was superior than that of single markers, with a sensitivity of 52.26% and specificity of 77.46% in the training group. Further assessment was studied in another validation group, with a sensitivity of 44.02% and specificity of 83%.
conclusionsThe diagnostic performance was enhanced by combining 7-AABs, CEA and CYFRA21-1, which has critical value for the screening and early detection of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.